Skip to Content

Posts tagged with "Clinical Trials"

  • Cancer

    Incomprehensible Drug Prices? Think Again.

    There’s a post by Peter Bach, of the Center for Health Policy and Outcomes, that’s been getting a lot of attention the last few days. It’s called “Unpronounceable Drugs, Incomprehensible Prices”, and you know what it says. No, really, you do, even if you haven’t seen it. Too high, unconscionable, market can’… Read More
  • Cancer

    Is The Current Patent System Distorting Cancer Research?

    Via the Economist‘s “Free Exchange” blog comes this provocative paper (PDF) from the University of Chicago, Harvard, and MIT. Its authors are looking at the effect of patents on the oncology drug market, and they conclude that the current system is probably hurting patients (and the broader economy). That’s a big statement t… Read More
  • Business and Markets

    Targacept Comes Up Empty, Yet Again

    Targacept’s attempt to salvage something by testing TC-5214 for overactive bladder has failed. John Carroll at FierceBiotech counts eight straight failed clinical trials from this company: a record? I don’t see anyone beating that very easily, that’s for sure. Nicotinic receptors have proven to be a very, very difficult field to w… Read More
  • Business and Markets

    Neratinib Comes Through For Puma

    Yet another entry in the “Why do people keep investing in biopharma?” files. Take a look at the case of Puma Biotechnology. Their stock was as high as $140/share earlier in the year, and it gradually deflated to the high 50s/low 60s as time went on. But yesterday, after hours, they reported unexpectedly good Phase… Read More
  • Alzheimer's Disease

    Targacept Fumbles the Bad News on Alzheimer’s

    Targacept has been working on some very hard therapeutic areas over the years, and coming up dry – dramatically so. They may have just done it again. They’ve been testing TC-1734 in Alzheimer’s over the last year or so, a partial agonist at nicotinergic receptors. That was a long-shot mechanism to start with, although to… Read More
  • Clinical Trials

    A Drug Candidate from NCATS

    I’ve written several times about the NIH’s NCATS program, their foray into “translational medicine”. Now comes this press release that the first compound from this effort has been picked up for development by a biopharma company. The company is AesRx (recently acquired by Baxter), and the compound is AES-103. This came from… Read More
  • Clinical Trials

    Studies Show? Not So Fast.

    Yesterday’s post on yet another possible Alzheimer’s blood test illustrates, yet again, that understanding statistics is not a strength of most headline writers (or most headline readers). I’m no statistician myself, but I have a healthy mistrust of numbers, since I deal with the little rotters all day long in one form or another. Read More
  • Alzheimer's Disease

    Alzheimer’s Bonds

    I wrote a couple of years ago about Andrew Lo of MIT, and his idea for securitization of drug discovery. For those of you who aren’t financial engineers, that means raising funds by issuing securities (bonds and the like), and that’s something that (as far as I know) has never been used to fund any… Read More
  • Clinical Trials

    Taking Risks – You Have To, So Do It Right

    In case you hadn’t seen it, I wanted to highlight this post by Michael Gilman over at LifeSciVC. He’s talking about risk in biotech, and tying it to the processes of generating, refining, and testing hypotheses. “The hypothesis”, he says, “is one of the greatest intellectual creations of our species”, and he̵… Read More
  • Clinical Trials

    Whooo-eee

    No time for a morning blog post – I’m too busy exhaling sighs of relief around here. I’ll see everyone later on in the day (on some other topic entirely). What a business this is! Read More
...192021...